Delving into the Latest Updates on Plozalizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-CCR2 monoclonal antibody, Plozalizumab (USAN/INN)

+ [3]

Target

CCR2

Mechanism

CCR2 antagonists(C-C chemokine receptor type 2 antagonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [5]

Active Indication-

Inactive Indication

AtherosclerosisDiabetic NephropathiesInflammation+ [2]

Originator Organization

Millennium Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Takeda Pharmaceutical Co., Ltd.

Millennium Pharmaceuticals, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 319372604H

Source: *****

Sequence Code 315596511L

Source: *****

The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 arms when administered to participants with advanced melanoma.

Start Date22 Jun 2016

Sponsor / Collaborator

Millennium Pharmaceuticals, Inc.

NCT02388971 / WithdrawnPhase 2

A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging

The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.

Start Date01 Apr 2016

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

EUCTR2014-005142-21-AT / Not yet recruitingPhase 2

A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Subjects with Macroalbuminuria - MLN1202 75, 105, 150 mg as add-on to ACE/ARB to treat Diabetic Nephropathy

Start Date21 Jul 2015

Sponsor / Collaborator

Takeda Development Centre Europe Ltd.

100 Clinical Results associated with Plozalizumab

Login to view more data

100 Translational Medicine associated with Plozalizumab

Login to view more data

100 Patents (Medical) associated with Plozalizumab

Login to view more data

24

Literatures (Medical) associated with Plozalizumab

01 Jan 2023·Bioinformatics and Biology Insights

A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study

Article

Author: Islam, Md. Kobirul ; Feroz, Tasmiah ; Shakil, Md. Shahariar Kabir ; Hossain, Md. Monir ; Noman, Abdulla Al

Having a previous history of sexually transmitted diseases (STDs) such as gonorrhea and chlamydia increases the chance of developing prostate cancer, the second most frequent malignant cancer among men. However, the molecular functions that cause the development of prostate cancer in persons with gonorrhea and chlamydia are yet unknown. In this study, we studied RNA-seq gene expression profiles using computational biology methods to find out potential biomarkers that could help us in understanding the patho-biological mechanisms of gonorrhea, chlamydia, and prostate cancer. Using statistical methods on the Gene Expression Omnibus (GEO) data sets, it was found that a total of 22 distinct differentially expressed genes were shared among these 3 diseases of which 14 were up-regulated (PGRMC1, TSC22D1, SH3BGRL, NNT, CTSC, FRMD3, CCR2, FAM210B, VCL, PTGS1, SLFN11, SLC40A1, PROS1, and DSE) and the remaining 8 genes were down-regulated (PRNP, HINT3, MARCKSL1, TMED10, SH3KBP1, ENSA, DERL1, and KMT2B). Investigation on these 22 unique dysregulated genes using Gene Ontology, BioCarta, KEGG, and Reactome revealed multiple altered molecular pathways, including regulation of amyloid precursor protein catabolic process, ferroptosis, effects on gene expression of Homo sapiens PPAR pathway, and innate immune system R-HSA-168249. Four significant hub proteins namely VCL, SH3KBP1, PRNP, and PGRMC1 were revealed by protein-protein interaction network analysis. By analyzing gene-transcription factors and gene-miRNAs interactions, significant transcription factors (POU2F2, POU2F1, GATA6, and HIVEP1) and posttranscriptional regulator microRNAs (hsa-miR-7-5p) were also identified. Three potential therapeutic compounds namely INCB3284, CCX915, and MLN-1202 were found to interact with up-regulated protein C-C chemokine receptor type 2 (CCR2) in protein-drug interaction analysis. The proposed biomarkers and therapeutic potential molecules could be investigated for potential pharmacological targets and activity in the fight against in patients with gonorrhea, chlamydia, and prostate cancer.

01 Dec 2022·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Epitope Mapping of an Anti-Mouse CCR2 Monoclonal Antibody (C₂Mab-6) Using Enzyme-Linked Immunosorbent Assay

Article

Author: Kato, Yukinari ; Yoshikawa, Takeo ; Tanaka, Tomohiro ; Tateyama, Nami ; Asano, Teizo ; Suzuki, Hiroyuki ; Okada, Yuki ; Li, Guanjie ; Kaneko, Mika K. ; Kobayashi, Hiyori ; Nanamiya, Ren ; Isoda, Yu

CC chemokine receptor type-2 (CCR2) is a member of the G protein-coupled receptors, and is mainly expressed on cell surface of immune cells. CCR2 binds to its ligand, C-C motif chemokine 2 (also named as monocyte chemoattractant protein-1), which involves in the tumor progression by modulating the tumor microenvironment. Therefore, the monoclonal antibody (mAb) targeting CCR2 could be one of the strategies for cancer treatment. In this study, we investigated the critical epitope of C₂Mab-6, an anti-mouse CCR2 (mCCR2) mAb developed by N-terminal peptides immunization. We first performed enzyme-linked immunosorbent assay (ELISA) using N-terminal peptides of mCCR2 and demonstrated that C₂Mab-6 recognizes 1-19 amino acids of mCCR2. We further performed ELISA using 20 alanine-substituted peptides of mCCR2. C₂Mab-6 lost the reaction to the alanine-substituted peptides of D3A, N4A, M6A, P8A, Q9A, and F10A. These results indicate that the binding epitope of C₂Mab-6 includes Asp3, Asn4, Met6, Pro8, Gln9, and Phe10 of mCCR2.

01 Aug 2022·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Development of an Anti-human CCR2 Monoclonal Antibody (C₂Mab-9) by N-Terminal Peptide Immunization

Article

Author: Kaneko, Mika K. ; Saito, Masaki ; Tanaka, Tomohiro ; Suzuki, Hiroyuki ; Kato, Yukinari ; Li, Guanjie ; Asano, Teizo

The CC chemokine receptor type-2 (CCR2) is one of the members of the G protein-coupled receptor superfamily, which are expressed on the cell surface of immune and tumor cells. CCR2 binds to the C-C motif chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1), which is produced by various cells, including tumor and immune-related cells. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR2 has been desired for treatment and diagnosis. In this study, we established a specific antihuman CCR2 (hCCR2) mAb, C₂Mab-9 (mouse IgG₁, kappa), using the synthetic peptide immunization method. Flow cytometric and immunocytochemical results showed that C₂Mab-9 reacted with hCCR2-expressing U937 (human histiocytic lymphoma) and natural killer cells. Furthermore, C₂Mab-9 showed the moderate binding affinity for both cells. Conclusively, C₂Mab-9 can be a useful tool for analyzing hCCR2-related biological responses.

100 Deals associated with Plozalizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10972	Plozalizumab	-	DB12520

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma	Phase 2	US	Millennium Pharmaceuticals, Inc.	22 Jun 2016
Inflammation	Phase 2	-	Takeda Pharmaceutical Co., Ltd.	01 Apr 2016
Diabetic Nephropathies	Phase 2	-	Takeda Pharmaceutical Co., Ltd.	20 May 2015
Atherosclerosis	Phase 2	-	Millennium Pharmaceuticals, Inc.	01 Aug 2005
Atherosclerosis	Phase 2	-	Millennium Pharmaceuticals, Inc.	01 Aug 2005
Multiple Sclerosis	Phase 2	-	Millennium Pharmaceuticals, Inc.	01 May 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02723006 (CTgov)	Phase 1	Melanoma	22	Nivolumab+TAK-580 (Arm 1: TAK-580 + Nivolumab)	nhkcrrttzg(pllqruhnmu) = fzxckhthtp gglexpgmzr (nmxoojldwt, tdfrfttide - xddbergvoo) View more	-	01 Apr 2021
NCT02723006 (CTgov)	Phase 1	Melanoma	22	Nivolumab+TAK-202 (Arm 2: TAK-202 + Nivolumab)	nhkcrrttzg(pllqruhnmu) = xuntsnojsm gglexpgmzr (nmxoojldwt, osaarwfqlx - mpjbwfcyim) View more	-	01 Apr 2021
NCT01015560 (S0916, CTgov)	Phase 2	Solid tumor \| Bone metastases	44	MLN1202	kfxkgrywtm(klgmxzngdx) = mvyxusdzua gqglswcmwl (xggxapulrf, adwjneilll - ozgaqoarle) View more	-	28 May 2014